EUVIMEDEUVIMED entdecken
Fallbericht

Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection

Wataru Ito, Tatsuya Fukumori, Nao Asaoka, Natsuko Imakita, Tomoko Nishimura, Ryutaro Furukawa, Yuji Nishihara, Hiroyuki Fujikura, Takahiro Sekine, Naoki Yamaguchi, Yuichiro Hirata, Sho Miyamoto und 4 weitere

Journal of Infection and Chemotherapy · 2024

DOI: 10.1016/j.jiac.2023.12.014 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Infection and Chemotherapy, 2024. Verfasst von Wataru Ito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Acalculous Cholecystitis, Ritonavir, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunocompromised patients with hematologic malignancies, particularly those treated with anti-CD20 antibodies such as rituximab and obinutuzumab, are known to be at risk of prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Prolonged administration or combination therapy with antiviral medications reportedly yields favorable outcomes in these patients. However, knowledge regarding the adverse events associated with such therapeutic approaches is limited. Herein, we report a case of acute acalculous cholecystitis (AAC) following extended administration of nirmatrelvir/ritonavir (NMV/r) in a 68-year-old Japanese man with persistent SARS-CoV-2 infection. The patient had received obinutuzumab and bendamustine for follicular lymphoma and was diagnosed with coronavirus disease 2019 (COVID-19) approximately one year after treatment initiation with these drugs. Subsequently, he was admitted to a different hospital, where he received antiviral drugs, monoclonal antibodies, and steroids. Despite these interventions, the patient relapsed and was subsequently transferred to our hospital due to persistent SARS-CoV-2 infection. Remdesivir administration was ineffective, leading to the initiation of extended NMV/r therapy. One week later, he exhibited elevated gamma-glutamyl transpeptidase (GGT) levels, and one month later, he developed AAC. Cholecystitis was successfully resolved via percutaneous transhepatic gallbladder drainage and administration of antibiotics. We speculate that extended NMV/r administration, in addition to COVID-19, may have contributed to the elevated GGT and AAC. During treatment of persistent SARS-CoV-2 infection with extended NMV/r therapy, patients should be carefully monitored for the appearance of findings suggestive of biliary stasis and the development of AAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acalculous CholecystitisRitonavirSARS-CoV-2COVID-19 Drug TreatmentCOVID-19Antiviral AgentsHumansMaleAgedAlanineLymphoma, FollicularImmunocompromised HostAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Acute acalculous cholecystitisGamma-glutamyl transpeptidaseLymphomaNirmatrelvir/ritonavirObinutuzumabPersistent SARS-CoV-2 infection

Substanzen

RitonavirAntiviral AgentsAlanineobinutuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan.
  • Department of Intensive Care Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
  • Department of Infectious Diseases, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
  • Department of Pathology, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
  • Department of Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan. Electronic address: kassan@naramed-u.ac.jp.

Zitieren

APA

Ito, W., Fukumori, T., Asaoka, N., Imakita, N., Nishimura, T., Furukawa, R., Nishihara, Y., Fujikura, H., Sekine, T., Yamaguchi, N., Hirata, Y., Miyamoto, S., Kanno, T., Katano, H., Suzuki, T., & Kasahara, K. (2024). Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection. Journal of Infection and Chemotherapy. https://doi.org/10.1016/j.jiac.2023.12.014

Vancouver

Ito W, Fukumori T, Asaoka N, Imakita N, Nishimura T, Furukawa R, et al. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection. Journal of Infection and Chemotherapy. 2024. doi:10.1016/j.jiac.2023.12.014

BibTeX
@article{Ito2024,
  author = {Ito, Wataru and Fukumori, Tatsuya and Asaoka, Nao and Imakita, Natsuko and Nishimura, Tomoko and Furukawa, Ryutaro and Nishihara, Yuji and Fujikura, Hiroyuki and Sekine, Takahiro and Yamaguchi, Naoki and Hirata, Yuichiro and Miyamoto, Sho and Kanno, Takayuki and Katano, Harutaka and Suzuki, Tadaki and Kasahara, Kei},
  title = {Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection},
  journal = {Journal of Infection and Chemotherapy},
  year = {2024},
  doi = {10.1016/j.jiac.2023.12.014}
}
Kostenlos starten →